Longevity Science Foundation, Miami, FL (2026)

06/03/2026

Hundreds of millions of women live longer than men, yet spend significantly more years in poor health. The gender gap between lifespan and healthspan is partly rooted in a longstanding imbalance in medical research. For much of modern medical history, the male body served as the default model for research and clinical practice. Women were frequently excluded from studies, underrepresented in clinical trials, and insufficiently reflected in the datasets used to shape diagnosis, treatment, and standards of care. The effects of that imbalance continue to influence health outcomes today.

Our mission is to make longevity accessible to everyone. As part of this effort, we support with the potential to improve global health within a meaningful timeframe. One example is our Female Fertility & Longevity grant call, which focuses on ovarian , hormonal health, and interventions that address one of the most consequential biological transitions in a woman's life – menopause. By supporting research in this area, we aim to advance a deeper understanding of the mechanisms that shape women's health across the lifespan.

Over the past months, we have published a series of evidence-based articles exploring key aspects of women's health, including:

▶️ Why midlife represents a major biological transition and how it affects the brain, cardiovascular system, bones, metabolism, mood, and pelvic health.

▶️ Hormone replacement therapy (HRT) explained in practical terms: who may benefit, when it may be appropriate, and what conversations to have with a menopause-informed clinician.

▶️ How cardiovascular disease and can manifest differently in women.

▶️ Practical guidance for women in their 40s and 50s – which questions to ask and where to begin.

▶️ Nutrition and exercise strategies that support mass, metabolic health, bone strength, and long-term independence.

▶️ What the evidence actually says about women's sleep, including the importance of consistency, sleep quality, and recovery.

The article below brings these topics together in a single resource. Rather than offering another collection of health tips, it provides a practical overview of what changes during this stage of life, which interventions are supported by evidence, and where important scientific uncertainties still remain. We also discuss how emerging research, including work supported by the LSF, may help close some of these knowledge gaps in the years ahead. If you've been looking for a comprehensive, evidence-based introduction to women's health, , and healthy aging, this is a good place to start.

Read the "Women's Health, In One Place" article here: https://longevity.foundation/tpost/c3xf0bipf1-womens-health-in-one-place

05/29/2026

Anthropic and the Gates Foundation have announced a four-year, $200 million partnership focused on deploying AI across global health, life sciences, education, and agriculture. The initiative combines grant funding, Claude usage credits, technical support, and the development of public datasets, benchmarks, and more.

A major component of the partnership centers on healthcare and biomedical research. According to both organizations, Anthropic’s Claude models will be applied to areas including vaccine development, disease surveillance, and the identification of potential therapeutic candidates for under-researched diseases such as polio, HPV, and preeclampsia. The collaboration will also include healthcare intelligence systems and evaluation frameworks designed to help researchers, governments, and public health organizations work with complex medical datasets more effectively.

This reflects a broader expansion of AI into healthcare-adjacent domains such as drug discovery and biomedical research, alongside novel applications in clinical and diagnostic settings. While many of these efforts are in their early stages, the broader trajectory is becoming increasingly difficult to ignore.

The implications for longevity and age-related disease research may also prove significant. Many biological processes associated with aging, (e.g., chronic inflammation, immune dysfunction, neurodegeneration) involve highly complex systems that generate enormous volumes of fragmented biological and clinical data. AI systems capable of assisting with pattern detection, hypothesis generation, target prioritization, and analysis can meaningfully accelerate parts of the research pipeline, particularly in places where conventional approaches remain slow and resource-intensive.

The LSF continues to monitor developments at the intersection of AI, biotechnology, and longevity science as these fields increasingly shape the future of healthcare and age-related disease research. We invite you to learn more about our work and funding focus: https://longevity.foundation/support-us

05/20/2026

The image below, sourced from Stifel's BioPharma Market Update (January 2026) (originally highlighted by on X), charts some of the most consequential biomedical innovations of the past decade.

From the approval of Kymriah for blood cancers in 2017 to Journavx for acute pain in 2025, the concentration of novel treatment modalities in a single decade has been remarkable by any historical measure. Each milestone represents years of scientific persistence and, behind it, a capital commitment made long before anyone knew whether the bet would pay off.

This critical piece largely remains unacknowledged: the drugs approved today were seeded by research often conducted 15 to 20 years ago, and sometimes longer. The pipeline that produces future breakthroughs is being built right now, in university labs and preclinical programs that generate no commercial revenue and offer no near-term ROI. This is where conventional financing sources, such as venture capital and private equity, are structurally limited. Without a clear market pathway, private capital cannot reach the science on which progress hinges.

What has historically filled that gap is public funding. When it diminishes, the gap does not close on its own. This is how drug development works: basic science receives backing, insights accumulate over years, a company eventually forms around a validated target, private capital arrives, and a decade or so later, a treatment reaches patients. If the first step is removed, the entire sequence stalls.

Nonprofit grant-making organizations like the LSF occupy a distinct position in this ecosystem. Unconstrained by return timelines or portfolio concentration risk, they can fund science that is too early, too speculative, or too neglected to attract commercial interest.

We operate in this niche because innovation demands it. The LSF channels philanthropic capital into high-impact early-stage research across geroscience, age-related disease, and underrepresented populations – the upstream science that will anchor the next generation of breakthroughs. The image below is an argument both for optimism about scientific achievement, and the urgency of our cause. If you believe in the case for early-stage, promising science and the role of philanthropic capital in sustaining it, we invite you to support our work: https://longevity.foundation/support-us

05/14/2026

What happens to cognition when AI does the heavy lifting?

A recent study published in Social Sciences & Humanities Open examined whether unrestricted access to ChatGPT during self-directed study helps or harms long-term knowledge retention. The trial, framed around the concept of ChatGPT as a cognitive crutch, offers one of the first experimental data points on a question that has largely been left to speculation.

The findings appear striking: students who used ChatGPT as a study aid scored significantly lower on a surprise retention test administered 45 days after learning (57.5%) than those who relied on traditional methods (68.5%). The AI-assisted group also spent substantially less time on the task, suggesting that access to ChatGPT reduced the effortful engagement that supports durable memory formation. These results fit into a broader and increasingly difficult-to-ignore pattern: as AI becomes a default resource for hundreds of millions of people worldwide, the cumulative effect on how we learn, remember, and process information is quietly compounding. The convenience of outsourcing cognitive work to a chatbot may come at a cost that does not always surface immediately.

None of this diminishes what AI is capable of: across healthcare, scientific research, financial services, and beyond, these tools are accelerating progress in ways that were unimaginable a decade ago. However, the question we should consider is where the line should be drawn. Offloading routine tasks is reasonable, but delegating ideation, information synthesis, and decision-making may present certain health risks. There is a meaningful difference between using AI to challenge assumptions and using it to replace the thinking we should be doing ourselves.

While the findings are thought-provoking and deserve attention, it is important to be mindful that this is a single study with a modest sample and conducted in a specific context. Replication across broader populations and varied AI use cases is needed before treating these results as definitive. What is clear, however, is that we need to be increasingly vigilant in our use of AI, and its impact on brain health at the individual level, within organizations, and across society. This conversation warrants ongoing attention. Learn more about the intersection of AI and cognition from our CEO's panel participation at the Future Proof Citywide conference here:

https://longevity.foundation/news/tpost/oem135ipg1-event-recap-the-lsf-at-the-future-proof

05/06/2026

Physical activity is one of the most consistently supported interventions linked to a lower biological age.

A recent systematic review and meta-analysis published in The Lancet Healthy Longevity examined how exercise relates to biological aging using DNA methylation clocks, widely used research tools that estimate biological age based on molecular patterns associated with aging.

The study reviewed 44 human studies, covering more than 145,000 participants across a wide age range. By aggregating data from multiple cohorts, the researchers assessed whether higher levels of physical activity were associated with differences in epigenetic age acceleration. The results suggest an overall pattern: individuals with higher physical activity levels tended to show lower biological age signals, particularly when measured using the Horvath and GrimAge clocks. In simple terms, more active individuals appeared biologically younger, although effect sizes were relatively modest and not all measures showed consistent associations. We are also pleased to see our Scientific Advisory Board member, Prof. Andrea B. Maier, among the contributing authors of this work.

Most of the available evidence comes from cross-sectional studies, limiting conclusions about causality. More longitudinal research will be needed to determine how exactly exercise influences aging trajectories over time. Still, the direction of the findings is broadly consistent with decades of research linking physical activity to improved health outcomes and reduced risk of age-related disease.

The takeaway is fairly straightforward: if the goal is to support healthy longevity, the starting point remains the fundamentals. Physical activity is not a marginal intervention or an emerging trend, but one of the most well-established and accessible ways to improve long-term health. We invite you to read the LSF’s articles covering the intersection of longevity, muscle, and physical activity: https://longevity.foundation/education #!/tfeeds/570878103061/c/Exercise%20&%20Muscle

05/01/2026

We’ve been running an LSF series on lifestyle interventions for longevity, starting with the big pillars like exercise, nutrition, and sleep. More recently, we added another pillar that’s just as critical for healthy aging: the brain. We began by looking at cognitive training and skill acquisition. Now we’re tackling two of the most heavily marketed brain interventions out there: mindfulness meditation and breathwork.

The claims are big: “rewire your brain in 8 weeks,” “boost vagal tone,” “slow aging,” even “trigger psychedelic release.” So we did what we always do in Hype vs Reality: follow the peer-reviewed evidence and separate what’s plausible from what’s just viral content.

𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀

▶️ hashtag helps… but it’s not magic. The strongest evidence supports improvements in stress, anxiety, and some aspects of attention/emotion regulation, not instant cognitive upgrades.
▶️ Biomarker effects are modest. hashtag and stress markers tend to shift only slightly on average, more “small nudge” than “full-body reset.”
▶️ “Brain rewiring in 8 weeks” is overhyped. Early small studies suggested structural brain changes, but more rigorous controlled work doesn’t reliably replicate that claim.
▶️ Breathwork can change how you feel fast, because of physiology. Intense breathing can alter CO₂ levels, which explains tingling, lightheadedness, and altered states better than unproven psychedelic narratives.
▶️ Longevity impact is likely indirect. If these tools help people manage stress and sleep, reduce blood pressure, or stick to healthier habits, they may support hashtag .

In conclusion, mindfulness and breathwork can be useful tools, especially for stress regulation, but the most popular claims often run far ahead of the data. If you’re building a hashtag portfolio, these practices make the most sense as adjuncts, while the heavy lifting for brain healthspan still comes from fundamentals like hashtag risk control, physical activity, sleep, and social connection.

If you want the evidence-based version, read the full piece here: https://longevity.foundation/tpost/ckvu8hlrp1-can-mindfulness-and-breathwork-keep-your

No time? You can skip to the end of the article for the key takeaways.

04/29/2026

Anthropic has been reported by multiple outlets to have acquired Coefficient Bio (acquired by Anthropic) in a transaction valued at approximately $400 million in stock, although some sources have described the deal as a strategic investment.

The news comes as Anthropic continues its push into healthcare and research, following the launch of Claude for Life Sciences. Available reporting suggests that Coefficient Bio’s team may be integrated into these efforts, with a focus on developing tools for workflows, suggesting a more direct approach to embedding AI capabilities within research environments rather than relying solely on external partnerships.

This is not an isolated incident. Several technology leaders and AI-adjacent companies are increasingly engaging with longevity and biotechnology. Altos Labs, backed in part by Jeff Bezos, is focused on cellular reprogramming, while Retro Biosciences is funded by Sam Altman with a similar ambition to extend human lifespan. NewLimit, co-founded by Brian Armstrong, is applying machine learning to epigenetic reprogramming. Continued deployment of significant capital and resources further illustrates sustained interest from the technology and AI sectors in extending human .

This trend points to a gradual convergence between AI, , and longevity science, driven by the growing integration of computational tools into and development. The LSF recognizes the need to leverage AI’s capabilities to further our understanding of biology and develop tools, therapies, and diagnostic methodologies that address age-related disease. Learn more about the scientific leadership behind our grant-making decisions here: https://longevity.foundation/support-us

Read the full article here: Link in the comments: https://www.theinformation.com/articles/anthropic-acquires-startup-coefficient-bio-400-million

04/16/2026

Researchers at Harvard have identified a mechanism that may enable wound healing without scarring by reactivating regeneration processes that shut down after birth. In a study conducted in mice, scientists demonstrated that skin injuries in the early stages of life can regenerate fully, restoring multiple cell types rather than forming scar tissue. The highlights a critical transition window around birth, during which regenerative capacity declines sharply. By identifying the molecular drivers of this shift, the team partially restored regenerative healing in wounds later in life.

The findings are potentially significant. The study shows that postnatal scarring is driven in part by connective tissue signaling that increases nerve density at wound sites, thereby disrupting the regeneration of other skin cell types. By reducing signaling through this pathway, researchers were able to promote more complete tissue restoration. This reframes wound healing as a process that may be improved by removing inhibitory mechanisms, rather than recreating complex conditions from scratch.

This line of research highlights the value of backing early-stage , where fundamental discoveries can redefine how entire fields evolve. Breakthroughs of this kind begin as uncertain ideas that require both time and resources to mature, yet they hold the potential to meaningfully improve and quality of life at scale. Expanding support for such work is essential to enabling bold experimentation and accelerating progress toward more proactive, prevention-focused, and accessible . We invite you to learn more about our work and see if building a healthier future resonates with you: https://longevity.foundation/support-us

Harvard University

04/14/2026

In March, our CEO, Joshua Herring, joined a panel at Future Proof Citywide titled “Your Brain on AI: What Changes and What Still Matters,” alongside Matt Halloran (Zocks) and Nyle Bayer (Future Proof).

The discussion focused on how AI is shaping the way we remember, focus, and process information, and what happens when we begin to offload parts of our thinking to these systems. It also touched on how AI is actively transforming healthcare and longevity research, while raising important questions about its longer-term impact on cognition and decision-making.

The conversation ultimately centered on a practical challenge: how to use AI in a way that supports human judgment rather than replaces it.

Watch the full panel and access our recap here: https://longevity.foundation/news/tpost/oem135ipg1-event-recap-the-lsf-at-the-future-proof

04/08/2026

As part of our Hype vs Reality mini-series on brain intervention and longevity, we looked at a topic that is everywhere in public health headlines and wellness marketing: loneliness.

You have probably seen the claims like “loneliness is the new smoking”, “having more friends will help you live longer”, and “fixing loneliness is a brain longevity intervention”.

Research shows that the truth is not that simple. Our latest article examines what the science actually says about loneliness, social isolation, strong relationships, brain health, and longevity, using primarily peer-reviewed human cohort studies, systematic reviews, and meta-analyses.

𝗞𝗲𝘆 𝗧𝗮𝗸𝗲𝗮𝘄𝗮𝘆𝘀

▶️ Loneliness and social isolation are not the same thing: Loneliness is the feeling of being disconnected. Social isolation is having fewer social ties or less contact. They overlap, but they are not interchangeable, and they may affect health differently.

▶️ Both are linked to worse health outcomes: A large meta-analysis of 90 prospective cohorts and around 2 million adults found a 33% higher risk of all-cause mortality for social isolation and a 14% higher risk for loneliness.

▶️ The impact is therefore not identical: Social isolation shows a stronger, more consistent association with mortality, while tends to have a smaller, more variable effect. Stronger social relationships are also associated with higher survival, but the evidence supports an association rather than simple causal claims.

▶️ For brain aging, social isolation may be the clearer signal: Across the literature, loneliness has been associated with higher risk of and cognitive decline. But in some very large cohort studies, social isolation showed a clearer and more robust link with dementia than loneliness itself after adjusting for factors like depression.

▶️ Relationship quality, support, and regular meaningful contact may matter more than the raw number of connections an individual maintains.

▶️ Many interventions help only modestly: Loneliness can be reduced, but most interventions show small to moderate effects rather than dramatic transformations. Psychological approaches may help more than simply increasing opportunities for contact, while many digital and commercial solution claims run ahead of the evidence.

If social disconnection truly contributes to poorer cognitive , then this is not just a well-being issue; it becomes a longevity issue too. This is also why we need to be careful. This is not an area for slogans, oversimplification, or “connection” products making promises beyond the data. The science supports a serious message: human connection matters for health, but it does not support every marketing claim made in its name.

Read the article for the evidence, the mechanisms, the limitations, and what the data really say about loneliness, strong relationships, and brain : https://longevity.foundation/tpost/glahy30z71-the-loneliness-epidemic-and-brain-aging

Longevity Science Foundation

06/03/2026

05/29/2026

05/20/2026

05/14/2026

05/06/2026

05/01/2026

04/29/2026

04/16/2026

04/14/2026

04/08/2026

Address

Website

Alerts

Contact The Organization

Shortcuts

Share

Category